


Alaska

1. AK S 32



Title: Biological Products

Summary: Relates to biological products; relates to the practice of pharmacy; relates to the Board of Pharmacy.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages

Disposition: Pending - Carryover


Introduced: 01/23/2017

Author: Hughes (R)

Status: 04/14/2017 From HOUSE Committee on HEALTH AND SOCIAL SERVICES: Do pass. (4-0)
04/14/2017 To HOUSE Committee on FINANCE.

Alabama

2. AL HJR 115



Title: Rare Disease Advisory Council


Summary: Establishes the Alabama rare disease advisory council.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.

Disposition: Enacted
Introduced: 03/02/2017
Author: Weaver (R)
Status: 03/29/2017 Signed by GOVERNOR.
03/29/2017 Act No. 2017-109


Arkansas

3. AR H 1204



Title: Biological Product Substitutions by Pharmacists
Summary: Allows pharmacists to make biological product substitutions; relates to pharmacy records, electronically accessible pharmacy records and pharmacy benefit management systems; requires a label showing the trade name or the proper name of the biological product.
NORD: NORD Supports
Disposition: Failed - Adjourned
Introduced: 01/18/2017
Author: Magie (D)
Status: 03/23/2017 WITHDRAWN by Author.


4. AR H 1900



Title: Health Insurance Coverage
Summary: Amends the requirements for health insurance coverage for medically necessary foods used in the treatment of inborn errors of metabolism; defines medical disorder requiring specialized nutrients or formulas; exempts benefits provided under the state Medicaid Program and certain limited benefit health insurance policies from these requirements.
Disposition: Enacted
Introduced: 03/03/2017
Author: Bentley (R)
Status: 04/07/2017 Signed by GOVERNOR.
04/07/2017 Act No. 1096

Arizona


5. AZ S 1368



Title: Newborn Screening and Fees
Summary: Relates to newborn screening; relates to fees.
NORD: NORD Supports
Disposition: Enacted
Introduced: 01/26/2017
Author: Allen (R)
Status: 05/22/2017 Chapter No. 339


California

6. CA A 1353



Title: Health Care Coverage: Prescription Drugs: Continuity
Summary: Requires a health care service plan and health insurer that provides coverage for outpatient prescription drugs to establish an expeditious process by which enrollees and insureds or prescribing providers may obtain an exception to any prior authorization process or any other utilization management or medical management practices. Requires coverage for certain medically necessary nonformulary drugs.
NORD: NORD Supports
Disposition: Pending
Introduced: 02/17/2017
Author: Waldron (R)
Status: 03/23/2017 From ASSEMBLY Committee on HEALTH with author's amendments.
03/23/2017 In ASSEMBLY. Read second time and amended. Re-referred to Committee on HEALTH.

7. CA ACR 14



Title: Rare Disease Day

Summary: Proclaims February 28, 2017, as Rare Disease Day in California and provides for the recognition of Rare Disease Day in subsequent years.


Disposition: Adopted

Introduced: 01/23/2017

Author: Nazarian (D)

Status: 04/05/2017 Chaptered by Secretary of State.
04/05/2017 Resolution Chapter No. 25

8. CA S 643



Title: Duchenne Muscular Dystrophy

Summary: Adds Duchenne muscular dystrophy to the list of medical conditions eligible for the Holden-Moscone-Garamendi Genetically Handicapped Persons Program.

NORD: NORD Supports. Actions: Submitted written testimony to health committee and participating in coalition in support of the bill.

Disposition: Pending


Introduced: 02/17/2017

Author: Pan (D)

Status: 06/27/2017 From ASSEMBLY Committee on HEALTH: Do pass to Committee on APPROPRIATIONS. (15-0)

Colorado

9. CO S 203



Title: Alternative Drug Requirement

Summary: Concerns the prohibition against a carrier requiring a covered person to undergo step therapy, and, in connection therewith, requiring coverage for a prescribed medication that is part of the carrier's medication formulary.

NORD: NORD Supports. Actions: Submitted written testimony.


Disposition: Enacted

Introduced: 02/28/2017

Sponsor: Todd (D)

Status: 06/07/2017 Session Law Chaptered. Chapter No. 296

10. **CT H 6009**



Title: Rare Disease Advisory Council

Summary: Establishes a rare disease advisory council; makes recommendations on legislation concerning the rare disease community.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.


Disposition: Failed

Introduced: 01/19/2017

Introducer: Rose (D)

Status: 03/29/2017 Failed Joint Favorable deadline.

11. **CT H 6622**



Title: Changes to Health Insurer Prescription Drug Formularies

Summary: Limits changes to health insurers' prescription drug formularies; limits when health insurance policies may change prescription drug formularies during a policy term.

NORD: NORD Supports


Disposition: Failed

Introduced: 01/24/2017

Introducer: Cook (D)

Status: 03/16/2017 Failed Joint Favorable deadline.

12. **CT H 7118**



Title: Biological Products

Summary: Concerns biological products; adds biological products to existing law regarding substitution of generic drugs.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.


Disposition: Failed - Adjourned

Introduced: 02/22/2017

Introducer: Joint Committee on General Law

Status: 05/25/2017 Senate Calendar No. 525.
05/25/2017 Reissued by Legislative Commissioner's Office with File No. 793.

13. CT S 22



Title: Cost Sharing for Prescription Drugs

Summary: Concerns cost-sharing for prescription drugs; assists citizens with prescription drug costs; imposes a coinsurance, copayment, deductible or other out-of-pocket expense that exceeds a specified sum for a covered prescription drug.

NORD: NORD Supports this legislation.


Disposition: Failed

Introduced: 01/09/2017

Introducer: Looney (D)

Status: 03/16/2017 Failed Joint Favorable deadline.

14. CT S 545



Title: Step Therapy Drug Regimens for Cancer Patients

Summary: Concerns a study of requests by health care providers to override step therapy drug regimens for certain cancer patients; requires a study and report on the processes that insurance companies, hospital service corporations, medical service corporations, health care centers and other entities that use step therapy for prescription drugs employ in assessing requests made by treating health care providers to override the use of step therapy drug regimens for insureds diagnosed with metastatic cancer.


Disposition: Failed

Introduced: 01/23/2017

Introducer: Kennedy (D)


Status: 03/16/2017 Failed Joint Favorable deadline.

15. **DE HCR 13**




Title: Rare Disease Day Resolution
Summary: Recognizes March 22, 2017, as "Rare Disease Day" in Delaware.
Disposition: Adopted
Introduced: 03/22/2017
Primary Sponsor: Baumbach (D)
Status: 03/22/2017 INTRODUCED.
 03/22/2017 Passed HOUSE. *****To SENATE.
 03/22/2017 Passed SENATE. (19-0)

16. **FL H 95**




Title: Nonmedical Changes To Prescription Drug Formularies
Summary: Relates to consumer protection from nonmedical changes to prescription drug formularies; limits changes to prescription drug formularies during health insurance policy or HMO contract year; provides applicability; exempts state group insurance program; requires small employer carriers to limit changes to prescription drug formularies under certain circumstances; changes to a health maintenance contract prescription drug formulary during a contracted year.
NORD: NORD supports this legislation.
Disposition: Failed
Introduced: 03/07/2017
Author: Massullo (R)
Status: 05/08/2017 In HOUSE. Died in committee.

17. **FL H 787**




Title: Health Insurance Coverage for Enteral Formulas
Summary: Relates to health insurance coverage for enteral formulas.
NORD: NORD supports this legislation.
Disposition: Failed
Introduced: 03/07/2017
Author: Slosberg E (D)
Status: 05/08/2017 In HOUSE. Died in committee.

18. FL H 963




Title: Newborn Screenings
Summary: Relates to newborn screenings; requires the Department of Health, upon the advice of the Genetics and Newborn Screening Advisory Council, to expand within a specified period the statewide screening of newborns to include any condition on the federal Recommended Uniform Screening Panel, contingent upon the availability of certain approved screening tests and an appropriation.
Disposition: Failed
Introduced: 03/07/2017
Author: Fitzenhagen (R)
Status: 04/27/2017 In HOUSE. Substituted on HOUSE floor by SB 1124
04/27/2017 In HOUSE. Laid on table, refer to SB 1124

19. FL S 182



Title: Prescription Drug Formularies
Summary: Relates to consumer protection from nonmedical changes to prescription drug formularies; limits changes to a health insurance policy prescription drug formulary during a policy year; requires small employer carriers to provide continuity of care for certain patients with respect to prescription drug coverage; limits changes to a health maintenance contract prescription drug formulary during a contract year.
NORD: NORD supports this legislation. Actions: Submitted written testimony.
Disposition: Failed
Introduced: 03/07/2017
Author: Mayfield D (R)

20. FL S 1124



Title: Newborn Screenings

Summary: Relates to newborn screenings; requires the Department of Health, upon the advice of the Genetics and Newborn Screening Advisory Council, to expand within a specified period the statewide screening of newborns to include any condition on the federal Recommended Uniform Screening Panel; requires the council to determine whether a condition should be included in the state's screening program; requires the department to submit a legislative budget request to fund additional testing.

NORD: NORD supports this legislation. Actions: Submitted written testimony.

Disposition: Enacted


Introduced: 03/07/2017

Author: Book (D)

Status: 06/09/2017 Signed by GOVERNOR.
06/12/2017 Filed as Chapter No. 2017-78

Georgia

21. GA H 241



Title: Krabbe Disease

Summary: Relates to control of hazardous conditions; adds Krabbe disease to the list of metabolic and genetic conditions for which newborn screening may be conducted pursuant to the Department of Public Health; provides for the screening at the option of the parent or parents; provides for payment of fees directly to the laboratory; relates to a system for prevention of serious illness, severe physical or developmental disability, and death resulting from inherited metabolic and genetic disorders.

NORD: NORD supports this legislation


Disposition: Enacted

Introduced: 02/02/2017

Author: Hawkins (R)

Status: 05/08/2017 Signed by GOVERNOR.
05/08/2017 Act No. 190

22. GA H 519



Title: Health Benefit Insurance Provisions

Summary: Relates to insurance generally, so as to require health benefit plans to utilize certain clinical review criteria to establish step therapy protocols; provides for a step therapy override determination process; provides for definitions; provides for statutory construction; provides for rules and regulations; provides for applicability; provides for related matters; repeals conflicting laws.

Disposition: Pending - Carryover


Introduced: 02/28/2017

Author: Cooper (R)

Status: 03/03/2017 In HOUSE: Read 2nd time.

Hawaii

23. HI H 1289



Title: Health Insurance

Summary: Establishes requirements for step therapy protocols to ensure patient access to the particular prescription drugs prescribed by health care providers; establishes insurance coverage requirements and standards for appeal of coverage determinations.


Disposition: Pending - Carryover

Introduced: 01/24/2017

Author: Belatti (D)

Status: 03/09/2017 Failed First Crossover Deadline - First Year of Biennium.

24. HI H 1525



Title: Prospective Review

Summary: Specifies procedural, disclosure, notice, and other requirements for prospective reviews required by health carriers or utilization review organizations prior to certification of coverage for health care services.


Disposition: Pending - Carryover

Introduced: 01/25/2017

Author: McKelvey (D)

Status: 03/09/2017 Failed First Crossover Deadline - First Year of Biennium.

25. **HI S 727**



Title: Rare Disease Advisory Board

Summary: Establishes the rare disease advisory board within the Department of Health to provide education about rare diseases and encourage the funding of research in the development of new treatments for rare diseases; describes duties of the advisory board, members of the board, and the board's obligation to coordinate with local and national groups conducting similar research and advocacy for persons with rare diseases.


Disposition: Pending - Carryover

Introduced: 01/20/2017

Author: Green (D)

Status: 03/09/2017 Failed First Crossover Deadline - First Year of Biennium.

26. **HI SCR 37**



Title: Rare Disease Task Force

Summary: Urges the establishment of a rare disease task force.

Disposition: Failed - Adjourned


Introduced: 01/24/2017

Author: Green (D)

Status: 04/06/2017 Failed First Crossover Deadline - First Year of Biennium.

Iowa

27. **IA H 31**



Title: Storing of Residual Newborn Screening Specimens

Summary: Relates to the storing of residual newborn screening specimens; includes effective date provisions.


Disposition: Pending - Carryover

Introduced: 01/18/2017

Author: Jones (R)

Status: 01/24/2017 In HOUSE Committee on HUMAN RESOURCES: Subcommittee assignments: R. Taylor, Chair, Bergan, Mascher.

28. IA H 233



Title: Step Therapy Protocols

Summary: Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations.


Disposition: Enacted

Introduced: 02/06/2017

Author: House Human Resources Committee

Status: 05/10/2017 Signed by GOVERNOR.

29. IA H 305



Title: Prescribing of Biological Products

Summary: Relates to the prescribing of biological products; makes penalties applicable.


Disposition: Enacted

Introduced: 02/14/2017

Author: House Human Resources Committee


Status: 03/10/2017 Signed by GOVERNOR.

30. IA HSB 26




Title: Step Therapy Protocols for Prescription Drugs
Summary: Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations; includes applicability provisions.
NORD: NORD supports this legislation. Actions: Submitted written testimony.
Disposition: Pending - Carryover
Introduced: 01/23/2017
Author: House Human Resources Committee
Status: 02/06/2017 In HOUSE. Becomes HOUSE File 233.

31. **IA HSB 38**




Title: Prescribing of Biological Products
Summary: Relates to the prescribing of biological products; makes penalties applicable.
Disposition: Pending - Carryover
Introduced: 01/24/2017
Author: House Human Resources Committee
Status: 02/14/2017 In HOUSE. Becomes HOUSE File 305.

32. **IA S 51**




Title: Testing of Newborns
Summary: Relates to a cytomegalovirus public health initiative and the testing of newborns for congenital cytomegalovirus; requires the center for congenital and inherited disorders to collaborate with state and local health agencies and other public and private organizations to develop and publish or approve and publish informational materials to educate and raise awareness of cytomegalovirus and congenital cytomegalovirus among women who may become pregnant, expectant parents, parents of infants.
NORD: NORD supports this legislation
Disposition: Enacted
Introduced: 01/11/2017
Author: Zaun (R)
Status: 04/20/2017 Signed by GOVERNOR.

33. IA S 326




Title: Prescribing of Biological Products
Summary: Relates to the prescribing of biological products; makes penalties applicable.
Disposition: Failed
Introduced: 02/22/2017
Author: Senate Human Resources Committee
Status: 03/01/2017 Withdrawn from further consideration.

34. IA S 436



Title: Step Therapy Protocols for Prescription Drugs
Summary: Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations; includes applicability provisions.
Disposition: Failed
Introduced: 03/03/2017
Author: Senate Human Resources Committee
Status: 04/10/2017 In SENATE. Filed Amendment No. S-3301.
04/10/2017 In SENATE. Adopted Amendment No. S-3301.
04/10/2017 In SENATE. HOUSE File 233 substituted.
04/10/2017 Withdrawn from further consideration.


35. IA SSB 1029



Title: Biological Products
Summary: Relates to the prescribing of biological products; makes penalties applicable.
Disposition: Pending - Carryover
Introduced: 01/27/2017

Author: Senate Human Resources Committee
Status: 02/22/2017 In SENATE. Becomes SENATE File 362.


36. **IA SSB 1072**



Title: Step Therapy Protocols
Summary: Relates to the use of step therapy protocols for prescription drugs by health carriers, health benefit plans, and utilization review organizations; including applicability provisions.
Disposition: Pending - Carryover
Introduced: 02/08/2017
Author: Senate Human Resources Committee
Status: 02/21/2017 In SENATE Committee on HUMAN RESOURCES: Passed subcommittee.

Illinois

37. **IL H 311**



Title: Network Adequacy and Transparency
Summary: Creates the Network Adequacy and Transparency Act; provides that administrators and insurers, prior to going to market, must file for review and approval a description of services to be offered through a network plan, with certain criteria included in the description; provides that the network plan shall demonstrate a minimum ratio of full-time equivalent providers to plan beneficiaries and maximum travel and distance standards; relates to telemedicine, telehealth, or mobile care services.
NORD: NORD supports this legislation. Actions: Submitted written testimony
Disposition: To Governor
Introduced: 01/11/2017
Sponsor: Harris G (D)
Status: 06/24/2017 HOUSE concurred in Senate Amendment No. 1. (98-0)
06/24/2017 Passed Both Houses.

38. **IL H 2694**



Title: Managed Care Reform and Patient Rights

Summary: Amends the Managed Care Reform and Patient Rights Act; in provisions concerning transition of services, provides that the health care plan shall not modify an enrollee's coverage of a drug during the plan year if the drug has been previously approved for coverage by the plan for a medical condition, the plan's prescribing provider continues to prescribe the drug for the medical condition, and the patient continues to be an enrollee of the health care plan.


Disposition: Pending

Introduced: 02/08/2017

Sponsor: Harris G (D)

Status: 03/31/2017 Rereferred to HOUSE Committee on RULES.

39. IL S 70



Title: Network Adequacy and Transparency

Summary: Creates the Network Adequacy and Transparency Act; provides that administrators and insurers, prior to going to market, must file with the Department of Insurance for review and approval a description of the services to be offered through a network plan, with certain criteria included in the description; provides that the network plan shall demonstrate to the Department, prior to approval, a minimum ratio of full-time equivalent providers to plan beneficiaries and maximum travel and distance standards.

Disposition: Pending


Introduced: 01/11/2017

Sponsor: Holmes (D)

Status: 05/05/2017 Rule 3-9(a) / Re-referred to ASSIGNMENTS Committee.

Indiana

40. IN S 73



Title: Electronic Authorization for Prescription Drugs


Summary: Relates to electronic authorization for prescription drugs; requires certain health plans to accept and respond to electronic prior authorization requests according to a particular electronic transaction standard.

NORD: NORD Supports this legislation.

Disposition: Enacted
Introduced: 01/03/2017
Author: Grooms (R)
Status: 04/13/2017 Signed by GOVERNOR.
04/13/2017 Public Law No. 45-2017


Kansas

41. **KS H 2107**




Title: Biological Product Inclusion and the Pharmacy Act
Summary: Relates to inclusion of biological products in the pharmacy act of the state of Kansas.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending - Carryover
Introduced: 01/19/2017
Author: House Health and Human Services Committee
Status: 03/08/2017 Senate Hearing: Thursday, March 16, 2017, 09:30 AM Room 118-N.

42. **KS H 2151**



Title: Health Insurance Use of Step Therapy Protocols
Summary: Establishes restrictions on health insurance use of step therapy protocols.
Disposition: Pending - Carryover
Introduced: 01/25/2017
Author: House Health and Human Services Committee
Status: 01/26/2017 To HOUSE Committee on HEALTH AND HUMAN SERVICES.


43. **KS S 82**



Title: Health Insurance Restrictions on Step Therapy Protocols
Summary: Establishes restrictions on health insurance use of step therapy protocols.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending - Carryover
Introduced: 01/25/2017
Author: Senate Public Health and Welfare Committee
Status: 02/08/2017 Senate Hearing: Monday, February 13, 2017, 09:30 AM Room 118-N.


Massachusetts

44. MA H 491




DOCKET 1498
Title: Transparency and Access in Healthcare
Summary: Relates to transparency and access in healthcare.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/23/2017
Author: Benson (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

45. MA H 492



DOCKET 1503
Title: Management of Medications
Summary: Relates to management of medications.
Disposition: Pending
Introduced: 02/23/2017
Author: Benson (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

46. MA H 1171



DOCKET 1591

Title: Rare Disease Advisory Council

Summary: Establishes a rare disease advisory council.


Disposition: Pending

Introduced: 01/23/2017

Author: Heroux (D)

Status: 06/27/2017 In JOINT Committee on PUBLIC HEALTH: Heard. Eligible for Executive Session.

47. MA H 1650



DOCKET 330

Title: Rare Disease Day Proclamation

Summary: Relates to the annual issuance of a proclamation by the Governor designating the last day of February as Rare Disease Day.


Disposition: Pending

Introduced: 02/24/2017

Author: Ashe (D)

Status: 02/27/2017 Filed as House Docket 330
02/27/2017 To JOINT Committee on STATE ADMINISTRATION AND REGULATORY OVERSIGHT. Dated 1/23/2017.

48. MA HD 390



DOCKET 1167


Title: Krabbe Disease in Newborn Screening

Summary: Includes Krabbe Disease in newborn screening.

NORD: NORD supports this legislation


Disposition: Pending
Author: Garry (D)
Status: 02/24/2017 Assigned House Bill No. 1167

49. MA HD 1591




DOCKET 1171
Title: Rare Disease Advisory Council
Summary: Creates a Massachusetts Rare Disease Advisory Council.
Disposition: Pending
Author: Heroux (D)
Status: 02/24/2017 Assigned House Bill No. 1171

50. MA HD 3712



DOCKET 3714
Title: Rare Disease Advisory Council
Summary: Creates a Massachusetts Rare Disease Advisory Council.
Disposition: Pending
Author: Heroux (D)
Status: 05/23/2017 Assigned House Bill No. 3714


51. MA S 516



DOCKET 1341
Title: Prescription Drug Coverage
Summary: Relates to out-of-pocket expenses for prescription drug coverage.


NORD: NORD supports this legislation. Actions: submitted written testimony.
Disposition: Pending
Introduced: 02/22/2017
Author: DiDomenico (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

52. MA S 542



DOCKET 1029
Title: Prescription Drug Coverage Out of Pocket Expenses
Summary: Makes out-of-pocket expenses for prescription drug coverage more affordable.
NORD: NORD supports this legislation. Actions: Submitted written testimony.
Disposition: Pending
Introduced: 02/22/2017
Author: Lesser (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

53. MA S 551



DOCKET 376
Title: Improved Medication Management
Summary: Reduces health care costs through improved medication management.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/22/2017
Author: L'Italien (D)
Status: 02/27/2017 To JOINT Committee on FINANCIAL SERVICES. Dated 1/23/2017.

54. MA SD 1341






DOCKET 516
Title: Prescription Drug Coverage Out of Pocket Expenses
Summary: Concerns out of pocket expenses for prescription drug coverage.
Disposition: Pending
Author: DiDomenico (D)
Status: 02/24/2017 Assigned Senate Bill No. 516


Maryland

55. MD H 740



Title: Cancer Treatment Access Act
Summary: Prohibits a specified insurer, nonprofit health service plan, or health maintenance organization from imposing a step therapy or fail-first protocol on an insured or an enrollee for a specified prescription drug used in the treatment of a specified cancer under specified circumstances.
Disposition: Enacted
Introduced: 02/02/2017
Author: Angel (D)
Status: 05/25/2017 Signed by GOVERNOR.
05/25/2017 Chapter No. 678


56. MD H 1128



Title: Prescription Drugs
Summary: Prohibits insurers, nonprofit health service plans, and health maintenance organizations from making specified formulary changes during a plan year and the open enrollment period that precedes the plan year; applies the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after the specified date.
Disposition: Failed
Introduced: 02/09/2017
Author: Kelly A (D)

Status: 03/14/2017 From HOUSE Committee on HEALTH AND GOVERNMENT OPERATIONS:
Reported unfavorably. (22-0)
03/14/2017 Withdrawn from further consideration.

57. MD H 1273



Title: Pharmacists Substitution

Summary: Authorizes a pharmacist to substitute an interchangeable biological product for a prescribed product under specified circumstances; requires a pharmacist or the pharmacist's designee, except under specified circumstances, to inform specified consumers of the availability of an interchangeable biological product and the approximate cost difference as compared to a specified drug; requires the State Board of Pharmacy to maintain on its Web site a link to specified lists of biological products.

NORD: NORD supports this legislation.


Disposition: Enacted

Introduced: 02/10/2017

Author: Cullison (D)

Status: 05/25/2017 Signed by GOVERNOR.
05/25/2017 Chapter No. 726

58. MD S 768



Title: Health Insurance

Summary: Prohibits insurers, nonprofit health service plans, and health maintenance organizations from making specified formulary changes during the plan year and the open enrollment period that precedes the plan year; applies the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after October 1, 2017.

Disposition: Failed

Introduced: 02/03/2017

Author: Feldman (D)

Status: 03/13/2017 From SENATE Committee on FINANCE: Reported unfavorably. (11-0)
03/13/2017 Withdrawn from further consideration.

59. MD S 997





Title: Pharmacists Substitution

Summary: Authorizes a pharmacist to substitute an interchangeable biological product for the prescribed product under specified circumstances; requires a pharmacist or the pharmacist's designee, except under specified circumstances, to inform specified consumers of the availability of an interchangeable biological product and the approximate cost difference as compared to a specified drug; requires the State Board of Pharmacy to maintain on its Web site a link to a specified list of biological products.

NORD: NORD supports this legislation. Actions: Submitted written testimony.

Disposition: Vetoed


Introduced: 02/03/2017

Author: Conway J (D)

Status: 05/26/2017 Vetoed by GOVERNOR - Duplicative.

Maine

60. ME H 198



LD 265

Title: Lysosomal Storage Disorders Newborn Screening

Summary: Requires the Department of Health and Human Services to amend its rules in Chapter 283 relating to the newborn screening program by January 1, 2018 to add to the program the lysosomal storage disorders known as Krabbe, Pompe, Gaucher, Fabry and Niemann-Pick diseases. It directs the department to explore options to enter into contracts with other states to test samples collected for lysosomal storage disorders.

NORD: NORD supports this legislation

Disposition: Failed

Introduced: 01/27/2017

Author: Johansen (R)

Status: 05/11/2017 SENATE accepts Committee Report.
05/11/2017 SENATE adopts Majority Committee Report: Ought not to pass.
05/11/2017 In SENATE. Placed in Legislative File (DEAD).

61. ME LR 1195



Title: Prescription Drug Step Therapy
Summary: Regards prescription drug step therapy.
Disposition: Pending
Author: Senator Rosen
Status: 04/07/2017 Assigned Senate Paper number 485 and LD 1407

Michigan


62. MI HR 28



Title: Rare Disease Day Resolution
Summary: Declares February 28, 2017, as Rare Disease Day in the state of Michigan.
Disposition: Adopted
Introduced: 02/28/2017
Sponsor: Faris (D)
Status: 02/28/2017 INTRODUCED.
02/28/2017 In HOUSE. Passed HOUSE.


Minnesota

63. MN H 712



Title: Standards of Biological Products Substitution
Summary: Relates to health; modifies and adds definitions; establishes standards for the substitution of biological products.
NORD: NORD supports this legislation
Disposition: Enacted
Introduced: 02/01/2017
Author: Albright (R)
Status: 05/23/2017 Signed by GOVERNOR.
05/23/2017 Filed with Secretary of State. Chapter No. 84

64. MN S 1184



Title: Biological Product Substitutions

Summary: Relates to health; modifies and adds definitions; establishes standards for the substitution of biological products.

Disposition: Failed


Introduced: 02/20/2017

Author: Nelson C (R)

Status: 05/09/2017 Indefinitely postponed. See H. B. 712.

Missouri

65. MO H 66



Title: Newborn Screening Requirements

Summary: Expands the newborn screening requirements to include spinal muscular atrophy (SMA) and Hunter syndrome.

NORD: NORD supports this legislation

Disposition: Failed - Adjourned


Introduced: 01/04/2017

Sponsor: Ruth (R)

Status: 04/10/2017 Placed on Informal Calendar.

Montana

66. MT H 233



Title: Drug Product Selection Act

Summary: Revises drug product selection laws to include biological products; provides definitions; requires reporting of drug product selection.


NORD: NORD supports this legislation. Actions: Submitted written testimony.

Disposition: Enacted

Introduced: 01/12/2017
Author: Ehli (R)
Status: 02/22/2017 Chaptered. Chapter No. 42

North Carolina

67. NC H 270



Title: Newborn Screening

Summary: Directs the commission for public health to adopt rules to add a screening test for Pompe disease, Mucopolysaccharidosis Type I, and X-linked Adrenoleukodystrophy to the newborn screening program; increases the fee for newborn screening tests; appropriates funds to the Department of Health and Human Services, division of public health, to purchase necessary equipment and upgrades at the state laboratory of public health for newborn screening and all other laboratory operations.

NORD: NORD supports this legislation


Disposition: Pending

Introduced: 03/08/2017

Author: Lambeth (R)

Status: 03/08/2017 INTRODUCED.
03/08/2017 To HOUSE Committee on HEALTH.

68. NC S 190



Title: Newborn Screening

Summary: Directs the commission for public health to adopt rules to add a screening test for Pompe disease, Mucopolysaccharidosis Type I, and X-linked Adrenoleukodystrophy to the newborn screening program; increases the fee for newborn screening tests; appropriates funds to the Department of Health and Human Services, division of public health, to purchase necessary equipment and upgrades at the state laboratory of public health for newborn screening and all other laboratory operations.

Disposition: Pending


Introduced: 03/07/2017

Author: Davis D (D)

Status: 03/07/2017 INTRODUCED.
03/07/2017 To SENATE Committee on RULES AND OPERATIONS OF THE SENATE.

North Dakota

69. ND H 1187



Title: Medical Food Program for Phenylketonuria

Summary: Relates to the medical food program for phenylketonuria or maple syrup urine disease; relates to treatment for a positive diagnosis; provides for a registry of cases of metabolic diseases; provides for medical food for persons under a specified age regardless of income; relates to low-protein modified food products; provides for reimbursement from any government program that provides coverage to that individual for the treatment services provided by the department.

NORD: NORD supports this legislation

Disposition: Enacted

Introduced: 01/09/2017

Author: Delmore (D)

Status: 03/21/2017 Signed by GOVERNOR.

Nebraska

70. NE L 481



Title: Interchangeable Biological Products Drug Selections

Summary: Relates to the Pharmacy Practice Act; provides, changes and transfers definitions; restates intent and changes provisions relating to drug product selection; provides for drug product selection for interchangeable biological products.

NORD: NORD supports this legislation. Actions: Submitted written testimony.

Disposition: Enacted

Introduced: 01/17/2017

Author: Kuehn (NP)

Status: 05/09/2017 Signed by GOVERNOR.

New Hampshire

71. NH H 443



Title: Prescription Drug Manufacturers

Summary: Prohibits prescription drug manufacturers from offering to pay or reimburse an individual for his or her insurance copayment.

Disposition: Failed


Introduced: 01/05/2017

Author: Kurk (R)

Status: 03/08/2017 Failed to pass HOUSE.

New Jersey

72. NJ A 817



Title: Disorders in Newborn Screening Program

Summary: Expands number of disorders included in newborn screening program.

NORD: NORD supports this legislation


Disposition: Pending

Introduced: 01/27/2016

Sponsor: Jimenez (D)

Status: 01/27/2016 INTRODUCED.
01/27/2016 To ASSEMBLY Committee on WOMEN AND CHILDREN.

73. NJ A 902



Title: Newborn Screening Specimen Disposal

Summary: Requires Department of Human Services (DHS) to dispose of newborn screening specimens within 60 days after testing.


Disposition: Pending

Introduced: 01/27/2016

Sponsor: Vainieri Huttel (D)

Status: 01/27/2016 INTRODUCED.
01/27/2016 To ASSEMBLY Committee on WOMEN AND CHILDREN.

74. NJ A 2337



Title: Patient Cost Sharing

Summary: Requires health insurers to limit patient cost-sharing and provide appeal process concerning certain prescription drug coverage.

NORD: NORD supports this legislation and provided in-person testimony and constituent visits during Rare Disease Day.


Disposition: Pending

Introduced: 02/04/2016

Sponsor: Benson (D)

Status: 10/06/2016 From ASSEMBLY Committee on FINANCIAL INSTITUTIONS AND INSURANCE. (10-0)

75. NJ A 3137



Title: Rare Disease Advisory Council

Summary: Establishes the New Jersey Rare Disease Advisory Council.


Disposition: Pending

Introduced: 02/22/2016

Sponsor: Dancer (R)

Status: 02/22/2016 INTRODUCED.
02/22/2016 To ASSEMBLY Committee on HEALTH AND SENIOR SERVICES.

76. NJ S 814



Title: Health Insurers to Limit Patient Cost Sharing

Summary: Requires health insurers to limit patient cost-sharing and provide appeal process concerning certain prescription drug coverage.


Disposition: Pending

Introduced: 01/12/2016

Sponsor: Weinberg (D)

Status: 06/22/2017 Received in the ASSEMBLY without Reference.

77. NJ S 1283



Title: Newborn Screening Program

Summary: Revises Newborn Screening program in Department of Health.


Disposition: Pending

Introduced: 02/08/2016

Sponsor: Vitale (D)

Status: 02/08/2016 INTRODUCED.
02/08/2016 To SENATE Committee on HEALTH, HUMAN SERVICES AND SENIOR CITIZENS.

78. NJ S 1929



Title: Insurance Coverage for Elemental Formula

Summary: Requires health insurance coverage for amino acid-based elemental formula.


Disposition: Pending

Introduced: 03/10/2016

Sponsor: Lesniak (D)

Status: 03/10/2016 INTRODUCED.
03/10/2016 To SENATE Committee on COMMERCE.

79. NJ SJR 33



Title: Rare Disease Awareness Day

Summary: Designates last day of February of each year as Rare Disease Awareness Day in New Jersey.

Disposition: Pending

Introduced: 02/11/2016


Sponsor: Bucco AR (R)

Status: 02/11/2016 INTRODUCED.

02/11/2016 To SENATE Committee on HEALTH, HUMAN SERVICES AND SENIOR CITIZENS.

New Mexico

80. NM H 244



Title: Prescription Drug Coverage Step Therapy

Summary: Relates to health coverage; enacts new sections of the health care purchasing act, the public assistance act, the New Mexico insurance code, the health maintenance organization law and the nonprofit health care plan law to establish guidelines relating to step therapy for prescription drug coverage.

NORD: NORD supports this legislation. Actions: Submitted written testimony.


Disposition: Failed - Adjourned

Introduced: 01/25/2017

Author: Thomson (D)

Status: 03/11/2017 From SENATE Committee on CORPORATIONS AND TRANSPORTATION: Do pass as amended.

81. NM H 260



Title: Regulation of Biosimilar Products

Summary: Relates to health; amends the New Mexico Drug, Device and Cosmetic Act to provide for regulation of biosimilar products.


Disposition: Enacted

Introduced: 01/26/2017

Author: Armstrong (D)

Status: 04/06/2017 Signed by GOVERNOR.
04/06/2017 Chaptered. Chapter No. 48

82. NM S 179



Title: Prescription Drug Coverage Step Therapy

Summary: Relates to health coverage; enacts new sections of the health care purchasing act, the public assistance act, the New Mexico insurance code, the health maintenance organization law and the nonprofit health care plan law to establish guidelines relating to step therapy for prescription drug coverage.


Disposition: Failed - Adjourned

Introduced: 01/25/2017

Author: Stefanics (D)

Status: 03/01/2017 From SENATE Committee on CORPORATIONS AND TRANSPORTATION: Do pass as amended.
03/01/2017 Re-referred to SENATE Committee on FINANCE.

83. NM S 180



Title: Regulation of Biosimilar Products

Summary: Relates to health; amends the New Mexico drug, device and cosmetic act to provide for regulation of biosimilar products.

Disposition: Failed - Adjourned

Introduced: 01/25/2017

Author: Ortiz y Pino (D)

Status: 03/11/2017 From HOUSE Committee on BUSINESS AND INDUSTRY: Do pass.

84. NM SM 108



Title: World Rare Disease Day

Summary: Declares February 28, 2017 World Rare Disease Day in the Senate.


Disposition: Adopted

Introduced: 02/27/2017

Author: Rodriguez (D)

Status: 02/28/2017 In SENATE. Withdrawn from table.
02/28/2017 Passed SENATE. (42-0)

85. NV A 245



Title: Dispensing of Biological Products

Summary: Relates to pharmacy; requires a pharmacist or his or her designee to make certain entries any time a biological product is dispensed under certain circumstances; requires the dispensing of an interchangeable biological product in substitution for a prescribed biological product under certain circumstances; requires the State Board of Pharmacy to maintain certain lists of approved interchangeable biological products, published by the United States Food and Drug Administration, on its Internet website.


Disposition: Enacted

Introduced: 02/27/2017

Author: Benitez-Thompso (D)

Status: 05/26/2017 Signed by GOVERNOR.
05/26/2017 Chaptered. Chapter No. 143

86. NV S 265



Title: Prescription Drugs

Summary: Relates to prescription drugs; requires the Department of Health and Human Services to compile a list of prescription drugs essential for treating diabetes; requires the manufacturer of a prescription drug included on the list to report certain information; requires a manufacturer to notify the Department in advance of planned price increases; provides for requirements concerning pharmaceutical sales representatives, contributions to certain nonprofit organizations, private schools, and insurer notices.

NORD: NORD opposes this legislation because it put onerous requirements on non-profits and applies provisions that could impact rare disease research.

Disposition: Vetoed

Introduced: 03/14/2017

Author: Cancela (D)

Status: 06/02/2017 Vetoed by GOVERNOR.

New York

87. NY A 1076



Title: DNA Testing for Newborns

Summary: Requires hospitals to provide parents of newborns with the option to have a DNA test performed on their child or have a blood sample taken from the child and preserved for future DNA testing.


Disposition: Pending

Introduced: 01/10/2017

Sponsor: Pretlow (D)

Status: 01/10/2017 INTRODUCED.
01/10/2017 To ASSEMBLY Committee on HEALTH.

88. NY S 4788



Title: Interchangeable Biological Products

Summary: Relates to interchangeable biological products; enacts provisions relating to substitutions of biological products by pharmacists.

NORD: NORD supports this legislation.

Disposition: Pending


Introduced: 03/01/2017

Sponsor: Hannon (R)

Status: 06/21/2017 Withdrawn from SENATE Committee on HIGHER EDUCATION.
06/21/2017 To SENATE Committee on RULES.
06/21/2017 From SENATE Committee on RULES. (23-1)
06/21/2017 Substituted by A7509A

Ohio

89. OH H 72



Title: Step Therapy Protocol Requirements


Summary: Adopts requirements related to step therapy protocols implemented by health plan issuers and the Department of Medicaid.

Disposition: Pending

Introduced: 02/21/2017

Sponsor: Johnson (R)
Status: 02/28/2017 From HOUSE Committee on RULES AND REFERENCE: Recommended referral.
02/28/2017 In HOUSE. To second reading. Read a second time.
02/28/2017 To HOUSE Committee on HEALTH.


90. OH S 56



Title: Step Therapy Protocols
Summary: Adopts requirements related to step therapy protocols implemented by health plan issuers and the Department of Medicaid.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/14/2017
Sponsor: Lehner (R)
Status: 02/15/2017 From SENATE Committee on RULES AND REFERENCE: Recommended referral.
02/15/2017 In SENATE. To second reading. Read a second time.
02/15/2017 To SENATE Committee on HEALTH, HUMAN SERVICES, AND MEDICAID.

Oregon

91. OR D 1255



Title: Health Authority
Summary: Directs Oregon Health Authority to establish and operate statewide database for collection and dissemination of orders for rare disease emergency response medical treatment for the purpose of ensuring safe treatment of individuals with rare diseases in emergency situations; creates Oregon ORDER Database Advisory Committee to advise authority on establishment, operation and evaluation of database.
NORD: NORD supports this legislation. Actions: provided in-person testimony and legislative visits as part of Rare Disease Day
Disposition: Pending
Author: Senate Committee on Education and General Government
Status: 02/01/2017 Assigned SENATE Bill No. 215

92. OR D 1743

Passed Passed Passed Passed

Introduced Passed
1st Committee Passed
1st Chamber Passed
2nd Committee Passed
2nd Chamber Enacted



Title: Prescription Drug Formulary for Insurance Code
Summary: Defines prescription drug formulary for purposes of Insurance Code; requires carrier offering health benefit plan to small employers, groups or individuals to make specified information about prescription drug formularies available on carrier's website and through toll-free telephone number; prohibits carrier from making changes to prescription drug formulary more than once every specified period unless based on alert issued by United States Food and Drug Administration.
Disposition: Pending
Author: Senate Committee on Health Care
Status: 12/12/2016 FILED.

93. **OR S 237**

Introduced Passed
1st Committee Passed
1st Chamber Passed
2nd Committee Passed
2nd Chamber Enacted



Title: Group Health Benefit Plans
Summary: Requires at least 25 percent of carrier's individual and group health benefit plans within each metal level of coverage to have copayment-only cost sharing requirements.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending
Introduced: 02/01/2017
Author: Joint Interim Human Services and Early Childhood Development
Status: 03/21/2017 Public Hearing held.

94. **OR S 526**


Introduced Passed
1st Committee Passed
1st Chamber Passed
2nd Committee Passed
2nd Chamber Enacted



Title: Step Therapy Protocol Imposed by Insurer
Summary: Modifies requirements applicable to step therapy protocol imposed by insurer; allows patient to appeal insurer's denial of step therapy override.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. In-person legislative visits during Rare Disease Day.
Disposition: Pending

Introduced: 02/01/2017
Author: Kruse (R)
Status: 02/21/2017 Public Hearing held.

95. **OR S 808**



Title: Health Testing Service

Summary: Provides that with respect to newborn screening, Oregon Health Authority shall specify that person providing newborn screening may conduct tests for conditions listed on most recent edition of Recommended Uniform Screening Panel by United States Department of Health and Human Services; specifies that person providing newborn screening shall test for certain condition through implementation of laboratory developed test approved by federal Food and Drug Administration, under certain circumstances.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. Conducted in-person legislative visits.

Disposition: Pending


Introduced: 02/16/2017

Author: Boquist (R)

Status: 04/24/2017 From SENATE Committee on HEALTH CARE: Do pass with amendment.
04/24/2017 Printed A Engrossed Text.
04/24/2017 To JOINT Committee on WAYS AND MEANS.

Pennsylvania

96. **PA H 239**



PN 2005

Title: Rare Disease Advisory Council Act

Summary: Establishes the Rare Disease Advisory Council and providing for its powers and duties; provides for duties of the Department of Health, the Insurance Department, the Department of Human Services and the Department of Education.

NORD: NORD supports this legislation. Actions: Submitted written testimony. Planning in-person legislative visits during Rare Disease Day in May.

Disposition: Pending

Introduced: 02/01/2017

Author: Toepel (R)

Status: 06/28/2017 In SENATE. Read third time. Passed SENATE. *****To HOUSE for

97. **PA HR 55**



PN: 277
Title: Rare Disease Day
Summary: Recognizes March 14, 2017, as "Rare Disease Day".
Disposition: Pending
Introduced: 02/02/2017
Author: Toepel (R)
Status: 03/20/2017 To HOUSE Committee on RULES.


98. **PA SR 29**



PN: 308
Title: Rare Disease Day
Summary: Recognizes February 28, 2017, as Rare Disease Day.
Disposition: Adopted
Introduced: 02/08/2017
Author: Costa J (D)
Status: 02/08/2017 FILED.
 02/08/2017 INTRODUCED.
 02/08/2017 Passed SENATE.

Rhode Island

99. **RI H 5636**




Title: Insurance Step Therapy Protocols
Summary: Would require health insurers, nonprofit hospital service corporations, nonprofit medical

service corporations and health maintenance organizations that issue policies that provide coverage for prescription drugs and use step therapy protocols, to base step therapy protocols on appropriate clinical practice guidelines or published peer review data developed by independent experts with knowledge of the condition or conditions under consideration; that patients be exempt from step therapy protocols/.

NORD: NORD supports this legislation. Actions: Submitted written testimony.
Disposition: Pending
Introduced: 03/01/2017
Author: Blazejewski (D)
Status: 04/04/2017 In HOUSE Committee on CORPORATIONS: Committee recommends measure to be held for further study.


South Carolina

100. SC H 3323



Title: Payment of Insurance Premiums
Summary: Allows the payment of insurance premiums and other cost sharing by third parties on behalf of individuals insured by qualified health plans.
NORD: NORD supports. Actions: Submitted written testimony and constituent messages. Conducted in-person legislative visits during Rare Disease Day.
Disposition: Pending - Carryover
Introduced: 01/10/2017
Author: Stringer (R)
Status: 01/10/2017 INTRODUCED.
01/10/2017 To HOUSE Committee on LABOR, COMMERCE AND INDUSTRY.


101. SC H 3438



Title: Drug Product Selection Act
Summary: Relates to definitions in the Drug Product Selection Act; includes interchangeable biological products in the definition of substitute; relates to the substitution of equivalent drugs; allows pharmacists to substitute interchangeable biological products when appropriate; relates to label requirements for prescriptions so as to include interchangeable biological products; requires pharmacies to keep records of dispensed biological products; requires a database for all approved biological products.
NORD: NORD supports this legislation. Actions: Submitted written testimony.

Disposition: Enacted
Introduced: 01/12/2017
Author: Henderson (R)
Status: 04/28/2017 Act No. 11

102. SC S 299



Title: Drug Product Selection Act

Summary: Relates to definitions in the Drug Product Selection Act; includes interchangeable biological products; relates to the substitution of equivalent drugs; allows a pharmacist to substitute an interchangeable biological product for a specific biological product; relates to the substitution of prescriptions by pharmacists; allows pharmacists to substitute interchangeable biological products when appropriate; relates to definitions in the pharmacy practice act; adds definitions for biological product.

Disposition: Pending - Carryover


Introduced: 01/24/2017

Author: Bryant (R)

Status: 01/24/2017 INTRODUCED.
01/24/2017 To SENATE Committee on MEDICAL AFFAIRS.

Tennessee

103. TN S 1138



Title: Pediatric Rare Disease Treatment Information Act

Summary: Relates to Children; enacts the Access to Pediatric Rare Disease Treatment Information Act; provides for sharing of essential treatment information for children with cancer among certain health care institutions.

Disposition: Pending - Carryover


Introduced: 02/09/2017

Author: Kyle (D)

Status: 02/13/2017 To SENATE Committee on HEALTH AND WELFARE.


Texas

104. TX H 1067




Title: Newborn Screening Tests for Adrenoleukodystrophy
Summary: Relates to newborn screening tests for adrenoleukodystrophy.
NORD: NORD supports this legislation.
Disposition: Failed - Adjourned
Introduced: 01/17/2017
Author: Meyer (R)
Status: 03/07/2017 Considered in public hearing.
03/07/2017 Testimony taken in committee.
03/07/2017 Left pending in committee.

105. TX H 1464



Title: Step Therapy Protocols for Health Benefit Plans
Summary: Relates to step therapy protocols required by a health benefit plan in connection with prescription drug coverage.
Disposition: Failed - Adjourned
Introduced: 02/01/2017
Author: Bonnen G (R)
Status: 05/08/2017 In HOUSE Tabled.

106. TX H 1917




Title: Contract Requirements for Prescription Drug Benefits
Summary: Relates to contract requirements for prescription drug benefits provided by Medicaid managed care organizations.
NORD: NORD supports and provided written testimony
Disposition: Enacted
Introduced: 02/15/2017

Author: Raymond (D)

Status: 06/15/2017 Signed by GOVERNOR.

107. TX H 1937



Title: Newborn Screening Tests for Adrenoleukodystrophy

Summary: Relates to newborn screening tests for adrenoleukodystrophy.


Disposition: Failed - Adjourned

Introduced: 02/15/2017

Author: Villalba (R)

Status: 03/13/2017 To HOUSE Committee on PUBLIC HEALTH.

108. TX S 680



Title: Health Benefit Plan Step Therapy Protocols

Summary: Relates to step therapy protocols required by a health benefit plan in connection with prescription drug coverage; provides a health benefit plan issuer that requires a step therapy protocol before providing coverage for a prescription drug must establish, implement, and administer the step therapy protocol in accordance with clinical review criteria readily available to the health care industry; provides the health benefit plan issuer shall take into account the needs of atypical patient populations.

NORD: NORD supports. Actions: Submitted written testimony and constituent messages. Conducted in-person legislative visits during and constituent outreach during Rare Disease Day.

Disposition: Enacted


Introduced: 01/31/2017

Author: Hancock (R)

Status: 06/13/2017 Filed with Secretary of State. Chapter No. 103

Utah

109. UT H 266



Title: Health Insurance Provisions

Summary: Amends health insurance provisions in the Insurance Code; prohibits the use of step therapy for pharmaceuticals unless certain conditions are met; requires a health insurer to authorize bypass of a step drug when certain conditions are met; addresses adverse benefit determinations.

NORD: NORD supports this legislation.

Disposition: Failed


Introduced: 02/01/2017

Author: Hutchings (R)

Status: 03/09/2017 Enacting clause struck.

Virginia

110. VA H 362



Title: Step Therapy Protocols

Summary: Relates to step therapy protocols; relates to disclosures; requires health insurers that limit coverage for prescription drugs through the use of a step therapy protocol to have in place a process for a prescribing provider to request an override of the protocol for a patient.


Disposition: Failed - Adjourned

Introduced: 01/13/2016

Author: Davis (R)

Status: 02/02/2016 In HOUSE Committee on COMMERCE AND LABOR: Continued to 2017.

111. VA H 601



Title: Health Insurance

Summary: Relates to health insurance; relates to mandated coverage for treatment of inborn errors of metabolism; requires health carriers to provide coverage for treatment of inborn errors of metabolism that involve amino acid, carbohydrate, and fat metabolism and for which medically standard methods of diagnosis, treatment, and monitoring exist.


Disposition: Failed - Adjourned

Introduced: 01/13/2016

Author: Murphy (D)

Status: 01/26/2016 In HOUSE Committee on COMMERCE AND LABOR: Continued to 2017.

112. VA H 1755



Title: Step Therapy Protocols

Summary: Relates to step therapy protocols; relates to disclosures; requires health insurers that limit coverage for prescription drugs through the use of a step therapy protocol to have in place a process for a prescribing provider to request an override of the protocol for a patient; provides that a step therapy protocol is a protocol or program that establishes the specific sequence in which prescription drugs for a specified medical condition are medically appropriate for a particular patient.


Disposition: Failed

Introduced: 01/11/2017

Author: Davis (R)

Status: 02/08/2017 In HOUSE Committee on COMMERCE AND LABOR: Left in committee.

113. VA S 331



Title: Step Therapy

Summary: Relates to step therapy; relates to psychiatric medicines; prohibits a health insurer or other carrier from using step therapy in a manner that results in a denial of or delay in coverage for any psychiatric medication under a health insurance policy or plan; applies only to health insurance policies or plans that provide coverage for prescription drugs on an outpatient basis; provides that if the health benefit plan utilizes a closed drug formulary, the prohibition applies only to psychiatric medications.


Disposition: Failed

Introduced: 01/13/2016

Author: DeSteph (R)

Status: 02/01/2016 In SENATE Committee on COMMERCE AND LABOR: Passed by indefinitely. (15-0)

114. VA S 332



Title: Step Therapy Protocols

Summary: Relates to step therapy protocols; requires health benefit plans that restrict the use of any prescription drug through the use of a step therapy protocol to have a clear, convenient, and expeditious process for a prescribing medical provider to request an override of such restrictions for a patient; requires website posting.


Disposition: Failed

Introduced: 01/13/2016

Author: DeSteph (R)

Status: 02/01/2016 In SENATE Committee on COMMERCE AND LABOR: Passed by indefinitely. (15-0)

115. VA S 1408



Title: Step Therapy Protocols

Summary: Relates to step therapy protocols; requires health benefit plans that restrict the use of any prescription drug through the use of a step therapy protocol to have in place a clear, convenient, and expeditious process for a prescribing medical provider to request an override of such restrictions for a patient.

Disposition: Failed


Introduced: 01/11/2017

Author: DeSteph (R)

Status: 01/23/2017 In SENATE Committee on COMMERCE AND LABOR: Passed by indefinitely. (9-6)

Vermont

116. VT H 65



Title: Health Coverage for Enteral Formula for Home Use

Summary: Relates to health insurance coverage for enteral formula for home use.

NORD: NORD supports this legislation.


Disposition: Pending

Introduced: 01/17/2017

Author: Weed (D)

Status: 01/18/2017 To HOUSE Committee on HEALTH CARE.

117. VT H 447



Title: Interchangeable Biological Products

Summary: Relates to interchangeable biological products.

NORD: NORD supports this legislation. Actions: Submitted written testimony.


Disposition: Pending

Introduced: 02/22/2017

Author: Copeland-Hanzas (D)

Status: 02/23/2017 To HOUSE Committee on HEALTH CARE.

118. VT S 19



Title: Out of Pocket Limit for Prescription Drugs

Summary: Relates to preserving the out-of-pocket limit for prescription drugs in bronze-level Exchange plans.

NORD: NORD supports this legislation.


Disposition: Pending

Introduced: 01/11/2017

Author: Ayer (D)

Status: 02/14/2017 SENATE Committee on HEALTH AND WELFARE relieved of further consideration.
02/14/2017 To SENATE Committee on FINANCE.

119. VT S 92



Title: Interchangeable Biological Products

Summary: Relates to interchangeable biological products.


NORD: NORD supports this legislation. Actions: Submitted written testimony.

Disposition: Pending

Introduced: 02/21/2017
Author: Lyons (D)
Status: 03/28/2017 To HOUSE Committee on HEALTH CARE.


Washington

120. **WA S 5626**



Title: Metastatic Cancer
Summary: Prohibits the use of step therapy in treatments for stage four advanced, metastatic cancer.
Disposition: Pending - Carryover
Introduced: 02/01/2017
Author: Miloscia (R)
Status: 06/21/2017 2017 3rd SPECIAL SESSION: By Order of Resolution - Reintroduced and retained in present status.


121. **WA S 5757**



Title: Step Therapy in Prescription Drug Coverage
Summary: Concerns use of step therapy in prescription drug coverage.
Disposition: Pending - Carryover
Introduced: 02/08/2017
Author: Rivers (R)
Status: 06/21/2017 2017 3rd SPECIAL SESSION: By Order of Resolution - Reintroduced and retained in present status.

West Virginia

122. **WV H 2300**



Title: Step Therapy Protocols

Summary: Regulates step therapy protocols in health benefit plans which provide prescription drug benefits; provides that upon the granting of a step therapy override determination, the health plan issuer or utilization review organization shall authorize coverage for the prescription drug prescribed by the patient's treating healthcare provider, provided such prescription drug is a covered prescription drug under such policy or contract.

NORD: NORD supports this legislation. Actions: Submitted written testimony.


Disposition: Enacted

Introduced: 02/09/2017

Sponsor: Kelly (R)

Status: 05/23/2017 Act No. 131

123. **WV S 49**



Title: Drug Benefits Prior Authorization Provisions

Summary: Requires provisions for prior authorization of drug benefits by insurers.


Disposition: Failed - Adjourned

Introduced: 02/08/2017

Sponsor: Ferns (R)

Status: 02/08/2017 INTRODUCED.
02/08/2017 To SENATE Committee on BANKING AND INSURANCE.

124. **WV S 526**



Title: Insurance Coverage for Inherited Enzymatic Disorders

Summary: Relates to mandatory insurance coverage, up to the age of twenty, for certain medical foods for amino acid-based formulas; provides a list of diagnosed conditions for which insurance coverage should extend; provides that coverage extends to medically necessary foods for home use when prescribed by a physician; defines terms; provides for exclusions.

NORD: NORD supports this legislation. Actions: Submitted written testimony and conducted constituent outreach to legislators.

Disposition: Failed - Adjourned

Introduced: 03/07/2017

Sponsor: Takubo (R)

Status: 03/31/2017 To HOUSE Committee on JUDICIARY.

*For more information, please contact
Tim Boyd at tboyd@rarediseases.org*
